Non-Ergot Dopamine Agonists Do Not Increase the Risk of Heart Failure in Parkinson’s Disease Patients: A Meta-Analysis of Randomized Controlled Trials

BACKGROUND: In recent years, some observational studies suggested that pramipexole, a non-ergot dopamine agonist (DA) used for the treatment of Parkinson’s disease (PD), may increase the risk of heart failure (HF). However, the limitations inherent in observational studies made it difficult to deter...

Descripción completa

Detalles Bibliográficos
Autores principales: De Vecchis, Renato, Cantatrione, Claudio, Mazzei, Damiana, Baldi, Cesare, Di Maio, Marco
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2016
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852778/
https://www.ncbi.nlm.nih.gov/pubmed/27222673
http://dx.doi.org/10.14740/jocmr2541e

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4852778/
https://www.ncbi.nlm.nih.gov/pubmed/27222673
http://dx.doi.org/10.14740/jocmr2541e

Ejemplares similares